Wird geladen...
Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?
Compelling evidence indicates Type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune effector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the con...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Landes Bioscience
2012
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3489759/ https://ncbi.nlm.nih.gov/pubmed/23162771 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.20368 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|